CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar

[News]

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.

More... (http://www.news-medical.net/news/20150604/CASI-files-application-with-CFDA-to-conduct-ENMD-2076-Phase-2-trial-in-fibrolamellar-carcinoma-patients.aspx)